Advertisement

Endoscopic Bariatric Therapies

  • Deepinder Goyal
  • Rabindra R. WatsonEmail author
Stomach and Duodenum (J Pisegna, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Stomach and Duodenum

Abstract

Obesity and its associated cardio-metabolic comorbidities have emerged as a global pandemic. The efficacy of various hypo-caloric diets and prescription drugs has been poor with respect to sustained weight loss. Recent advancements in endoscopic technology and techniques have opened a new field of minimally invasive endoscopic treatment options for combatting obesity both as a first line and adjunctive therapy. Presently, two endoscopic space-occupying devices in the form of intragastric balloons have received FDA approval for 6-month implantation in patients within a BMI range of 30–40 kg/m2. Furthermore, full-thickness suturing has led to the development of primary endoscopic sleeve gastroplasty and Roux-en-Y gastric bypass revision as viable endoscopic alternatives to surgical approaches. These techniques have the potential to reduce adverse events, cost, and recovery times. Looking forward, a variety of promising and novel medical devices and endoscopic platforms that target obesity and diabetes are in various phases of development and investigation. The present review aims to discuss the current and forthcoming endoscopic bariatric therapies with emphasis on relevant procedural technique and review of available evidence.

Keywords

Bariatric endoscopy Obesity Bariatric surgery Gastric bypass revision Intragastric balloon 

Notes

Compliance with Ethical Standards

Conflicts of Interest

DG declares that he has no conflicts of interest. RRW reports that he is a consultant for Apollo Endosurgery, outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303:235–41.CrossRefPubMedGoogle Scholar
  2. 2.
    Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282(16):1523–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Frohlich ED. Clinical management of the obese hypertensive patient. Cardiol Rev. 2002;10(3):127–38.CrossRefPubMedGoogle Scholar
  4. 4.
    Hall JE. Pathophysiology of obesity hypertension. Curr Hypertens Rep. 2000;2(2):139–47.CrossRefPubMedGoogle Scholar
  5. 5.
    Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360(9):859–73.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Gudzune KA, Doshi RS, Mehta AK, Chaudhry ZW, Jacobs DK, Vakil RM, et al. Efficacy of commercial weight-loss programs: an updated systematic review. Ann Intern Med. 2015;162(7):501–12.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kumar RB, Aronne LJ. Efficacy comparison of medications approved for chronic weight management. Obesity (Silver Spring). 2015;23 Suppl 1:S4–7.CrossRefGoogle Scholar
  8. 8.
    Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248–56.CrossRefPubMedGoogle Scholar
  9. 9.
    Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamon WD, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357(8):753.CrossRefPubMedGoogle Scholar
  10. 10.
    Avidor Y, Still C, Brunner M, Buchwald JN, Buchwald H. Primary care and subspecialty management of morbid obesity: referral patterns for bariatric surgery. Surg Obes Relat Dis. 2007;3:392–407.CrossRefPubMedGoogle Scholar
  11. 11.
    Kramer FM, Stunkard AJ, Spiegel TA, Deren JJ, Velchik MG, Wadden TA, et al. Limited weight losses with a gastric balloon. Arch Intern Med. 1989;149(2):411–3.CrossRefPubMedGoogle Scholar
  12. 12.••
    ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee, Abu Dayyeh BK, Kumar N, Edmundowicz SA, Jonnalagadda S, Larsen M, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82(3):425–438.e5. Summary of data on current EBTs.CrossRefGoogle Scholar
  13. 13.
    Lopez-Nava G, Rubio MA, Prados S, Pastor G, Cruz MR, Companioni E, et al. BioEnterics® intragastric balloon (BIB®). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons. Obes Surg. 2011;21(1):5–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Genco A, Bruni T, Doldi SB, Forestieri P, Marino M, Busetto L, et al. BioEnterics intragastric balloon: the Italian experience with 2,515 patients. Obes Surg. 2005;15(8):1161–4.CrossRefPubMedGoogle Scholar
  15. 15.
    Imaz I, Martínez-Cervell C, García-Alvarez EE, Sendra-Gutiérrez JM, González-Enríquez J. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18(7):841–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Barham K. Abu Dayyeh, Laura L. Eaton, George Woodman, Mark Fusco, Vafa Shayani, Helmuth T. Billy, Anita Courcoulas, Daniel J. Pambianco, Christopher J. Gostout. A randomized, multi-center study to evaluate the safety and effectiveness of an intragastric balloon as an adjunct to a behavioral modification program, in comparison with a behavioral modification program alone in the weight management of obese subjects. Abstract 444. Digestive Disease Week 2015, Washington, DC.Google Scholar
  17. 17.
    Forlano R, Ippolito AM, Iacobellis A, Merla A, Valvano MR, Niro G, et al. Effect of the BioEnterics intragastric balloon on weight, insulin resistance, and liver steatosis in obese patients. Gastrointest Endosc. 2010;71(6):927–33.CrossRefPubMedGoogle Scholar
  18. 18.
    Kotzampassi K, Grosomanidis V, Papakostas P, Penna S, Eleftheriadis E. 500 intragastric balloons: what happens 5 years thereafter? Obes Surg. 2012;22(6):896–903.CrossRefPubMedGoogle Scholar
  19. 19.
    Tai CM, Lin HY, Yen YC, Huang CK, Hsu WL, Huang YW, et al. Effectiveness of intragastric balloon treatment for obese patients: one-year follow-up after balloon removal. Obes Surg. 2013;23(12):2068–74.CrossRefPubMedGoogle Scholar
  20. 20.
    Zerrweck C, Maunoury V, Caiazzo R, Branche J, Dezfoulian G, Bulois P, et al. Preoperative weight loss with intragastric balloon decreases the risk of significant adverse outcomes of laparoscopic gastric bypass in super-super obese patients. Obes Surg. 2012;22(5):777–82.CrossRefPubMedGoogle Scholar
  21. 21.
    Dąbrowiecki S, Szczęsny W, Popławski C, Sosnowski D. Intragastric Balloon (BIB system) in the treatment of obesity and preparation of patients for surgery - own experience and literature review. Pol Przegl Chir. 2011;83(4):181–7.PubMedGoogle Scholar
  22. 22.•
    Ponce J, Woodman G, Swain J, Wilson E, English W, Ikramuddin S, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis. 2015;11(4):874–81. Pivotal FDA trial for intragastric balloon.CrossRefPubMedGoogle Scholar
  23. 23.
    Lopez-Nava G, Bautista-Castano I, Jimenez-Banos A, de Grado Manchado T, Fernandez-Corbelle J. A prospective evaluation of a new dual intragastric balloon. Obes Surg. 2014;24:1131.Google Scholar
  24. 24.
    Fogel R, De Fogel J, Bonilla Y, De La Fuente R. Clinical experience of transoral suturing for an endoluminal vertical gastroplasty: 1-year follow-up in 64 patients. Gastrointest Endosc. 2008;68(1):51–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Abu Dayyeh BK, Rajan E, Gostout CJ. Endoscopic sleeve gastroplasty: a potential endoscopic alternative to surgical sleeve gastrectomy for treatment of obesity. Gastrointest Endosc. 2013;78(3):530–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Kumar N, Sahdala HN, Shaikh S, Wilson E, Manoel GN, Zundel N, et al. Endoscopic sleeve gastroplasty for primary therapy of obesity: initial human cases. Gastroenterology. 2014;Mo1155:S-571–2.CrossRefGoogle Scholar
  27. 27.
    Lopez-Nava G, Galvão MP, da Bautista-Castaño I, Jimenez A, De Grado T, Fernandez-Corbelle JP. Endoscopic sleeve gastroplasty for the treatment of obesity. Endoscopy. 2015;47(5):449–52.PubMedGoogle Scholar
  28. 28.
    Lopez-Nava G, Galvão MP, Bautista-Castaño I, Jimenez-Baños A, Fernandez-Corbelle JP. Endoscopic sleeve gastroplasty: how I do it? Obes Surg. 2015;25(8):1534–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Sharaiha RZ, Kedia P, Kumta N, DeFilippis EM, Gaidhane M, Shukla A, et al. Initial experience with endoscopic sleeve gastroplasty: technical success and reproducibility in the bariatric population. Endoscopy. 2015;47(2):164–6.PubMedGoogle Scholar
  30. 30.
    Abu Dayyeh BK, Lautz DB, Thompson CC. Gastrojejunal stoma diameter predicts weight regain after Roux-en-Y gastric bypass. Clin Gastroenterol Hepatol. 2011;9(3):228–33.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Heneghan HM, Yimcharoen P, Brethauer SA, et al. Influence of pouch and stoma size on weight loss after gastric bypass. Surg Obes Relat Dis. 2012;8:408–15.CrossRefPubMedGoogle Scholar
  32. 32.
    Hallowell PT, Stellato TA, Yao DA, Robinson A, Schuster MM, Graf KN. Should bariatric revisional surgery be avoided secondary to increased morbidity and mortality? Am J Surg. 2009;197(3):391–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Dakin GF, Eid G, Mikami D, Pryor A, Chand B. Endoluminal revision of gastric bypass for weight regain – a systemic review. Surg Obes Rel Dis. 2013;9:335–43.CrossRefGoogle Scholar
  34. 34.•
    Thompson CC, Chand B, Chen YK, DeMarco DC, Miller L, Schweitzer M, et al. Endoscopic suturing for transoral outlet reduction increases weight loss following Roux-en-Y gastric bypass surgery. Gastroenterology. 2013;145(1):129–37. Randomized trial of TORe.CrossRefPubMedGoogle Scholar
  35. 35.
    Kumar N, Thompson CC. Comparison of a superficial suturing device with a full-thickness suturing device for transoral outlet reduction (with videos). Gastrointest Endosc. 2014;79(6):984–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Deepinder Goyal, Stephen Kim, Eric Dutson, Yijun Chen, Joseph Pisegna, Rabindra Watson. Endoscopic trans-oral outlet reduction in combination with gastroplasty (TORe-G) is a novel technique that is highly efficacious and safe for weight loss in patients with failed Roux-en-Y gastric bypass. American College of Gastroenterology Annual Meeting Oct 18, 2015. Honolulu, USA; Poster 186.Google Scholar
  37. 37.
    Espinos JC, Turro R, Mata A, et al. Early experience with the incisionless operating platform. Obes Surg. 2013;23:1375–83.CrossRefPubMedGoogle Scholar
  38. 38.
    López-Nava G, Bautista-Castaño I, Jimenez A, de Grado T, Fernandez-Corbelle JP. The primary obesity surgery endolumenal (POSE) procedure: one-year patient weight loss and safety outcomes. Surg Obes Relat Dis. 2015;11(4):861–5.CrossRefPubMedGoogle Scholar
  39. 39.
    Sullivan S, Stein R, Jonnalagadda S, Mullady D, Edmundowicz S. Aspiration therapy leads to weight loss in obese subjects: a pilot study. Gastroenterology. 2013;145(6):1245-52.e1-5.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Forssell H, Norén E. A novel endoscopic weight loss therapy using gastric aspiration: results after 6 months. Endoscopy. 2015;47(1):68–71.PubMedGoogle Scholar
  41. 41.••
    ASGE Bariatric Endoscopy Task Force; ASGE Technology Committee, Abu Dayyeh BK, Edmundowicz SA, Jonnalagadda S, Kumar N, Larsen M, et al. Endoscopic bariatric therapies. Gastrointest Endosc. 2015;81(5):1073–86. Concise summary of current endoscopic bariatric therapies.CrossRefGoogle Scholar
  42. 42.
    Ryou M, Agoston AT, Thompson CC. Endoscopic intestinal bypass creation by using self-assembling magnets in a porcine model. Gastrointest Endosc. 2015. Epub.Google Scholar
  43. 43.
    Lerner H, Whang J, Nipper R. Benefit-risk paradigm for clinical trial design of obesity devices: FDA proposal. Surg Endosc. 2013;27(3):702–7.CrossRefPubMedGoogle Scholar
  44. 44.••
    ASGE Bariatric Endoscopy Task Force, Sullivan S, Kumar N, Edmundowicz SA, Abu Dayyeh BK, Jonnalagadda SS, et al. ASGE position statement on endoscopic bariatric therapies in clinical practice. Gastrointest Endosc. 2015;82(5):767–72. Detailed report on proper implementation of EBT.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Center for Obesity and Metabolic Health (COMET), Division of Digestive DiseasesDavid Geffen School of Medicine at UCLA, UCLA Medical CenterLos AngelesUSA

Personalised recommendations